2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Virtual 04 June 2021 - 08 June 2021

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

04 Aug 2021 bởi

Adjuvant olaparib for 1 year following local treatment and adjuvant/neoadjuvant chemotherapy improved disease-free survival (DFS) in patients with HER2-negative early breast cancer (EBC) with BRCA1 or BRCA2 pathogenic/likely pathogenic variants and high recurrence risk, according to interim results of the multinational, phase III OlympiA study.

Adjuvant olaparib extends DFS in high-risk BRCA1/2-mutated HER2-negative early breast cancer

04 Aug 2021

Targeted radioligand therapy ups survival in previously-treated mCRPC

27 Jul 2021 bởi

Adding the lutetium-labelled PSMA*-617 (177Lu PSMA-617) targeted radioligand therapy to standard of care (SOC) led to significant extension of radiographic progression-free survival (rPFS) and overall survival (OS) compared with SOC alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who had progressed after treatment with chemotherapy and androgen inhibitors, according to the VISION trial presented at ASCO 2021.

Targeted radioligand therapy ups survival in previously-treated mCRPC

27 Jul 2021

Nivo–ipi, nivo–chemo present new first-line treatments for advanced oesophageal SCC

14 Jul 2021 bởi

The combination of nivolumab–ipilimumab (nivo–ipi) or nivolumab–chemotherapy (nivo–chemo) improved overall survival (OS) compared with chemotherapy alone in the first-line treatment of advanced oesophageal squamous cell carcinoma (ESCC), results of the phase III CheckMate 648 study showed.

Nivo–ipi, nivo–chemo present new first-line treatments for advanced oesophageal SCC

14 Jul 2021

JUPITER-02: Toripalimab plus chemo delays NPC progression

08 Jul 2021 bởi

Toripalimab added to chemotherapy in the first-line setting delayed disease progression in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC), according to results from the phase III JUPITER-02 trial presented at ASCO 2021.

JUPITER-02: Toripalimab plus chemo delays NPC progression

08 Jul 2021

Anti–PD-1 therapies may emerge as first-line SoC for R/M NPC

08 Jul 2021 bởi

Adding the anti–PD-1 monoclonal antibodies toripalimab or camrelizumab to first-line standard of care (SoC) with gemcitabine and cisplatin (GC) significantly improves progression-free survival (PFS) vs GC alone in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC), two phase III trials have shown. These results, reported at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021), may position toripalimab or camrelizumab in combination with GC as a new first-line SoC in this patient population.

Anti–PD-1 therapies may emerge as first-line SoC for R/M NPC

08 Jul 2021

Pimitespib a potential new standard treatment for GIST?

06 Jul 2021 bởi

The pivotal phase III CHAPTER-GIST-301 trial presented at ASCO 2021 demonstrated the potential of pimitespib, a novel oral inhibitor of heat shock protein 90 (HSP90), for the treatment of individuals with advanced gastrointestinal stromal tumours (GISTs) refractory to standard treatment (ie, imatinib, sunitinib, and regorafenib).

Pimitespib a potential new standard treatment for GIST?

06 Jul 2021

‘PACIFIC regimen’ shows long-term survival benefit with durvalumab in advanced NSCLC

06 Jul 2021 bởi

Improvements in overall survival (OS) and progression-free survival (PFS) were maintained with durvalumab in patients with unresectable stage III metastatic non-small cell lung cancer (NSCLC), according to updated results of the PACIFIC* trial presented at ASCO 2021.

‘PACIFIC regimen’ shows long-term survival benefit with durvalumab in advanced NSCLC

06 Jul 2021

Relatlimab-nivolumab combo boosts PFS in advanced melanoma

03 Jul 2021 bởi

A novel immune checkpoint inhibitor combination of relatlimab and nivolumab significantly extends progression-free survival (PFS) vs nivolumab alone in patients with untreated advanced melanoma in the phase II/III RELATIVITY-047 trial.

Relatlimab-nivolumab combo boosts PFS in advanced melanoma

03 Jul 2021

Hepatic arterial infusion chemo outdoes sorafenib for advanced liver cancer

02 Jul 2021 bởi

Hepatic arterial infusion chemotherapy consisting of a FOLFOX* regimen (HAIC-FO) showed superior efficacy over sorafenib in the first-line treatment of locally advanced or unresectable hepatocellular carcinoma (HCC), according to the findings of the phase III FOHAIC-1 study presented at ASCO 2021.

Hepatic arterial infusion chemo outdoes sorafenib for advanced liver cancer

02 Jul 2021

RATIONALE 302: Tislelizumab beats chemo in advanced ESCC

01 Jul 2021 bởi

Treatment with tislelizumab led to a significantly improved overall survival (OS) in patients with advanced or metastatic oesophageal squamous cell carcinoma (ESCC) compared with chemotherapy in the second-line setting, according to the RATIONALE 302* study presented at ASCO 2021.

RATIONALE 302: Tislelizumab beats chemo in advanced ESCC

01 Jul 2021